A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants
A Phase 1, Open-label, Positron Emission Tomography (PET) Imaging Study to Evaluate M4 Muscarinic Acetylcholine Receptor Occupancy in the Central Nervous System Using [11C]MK-6884 PET Tracer Before and After Oral Administration of Multiple Doses of BMS-986521 in Healthy Adult Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: First line of the email MUST contain NCT # and Site #.
Study Contact Backup
- Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
-
Contact:
- Koen Van Laere, Site 0001
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be healthy male and female (as assigned at birth) who are individuals not of childbearing potential (INOCBP) without clinically significant deviation from normal in medical history, PE, 12-lead ECG, and clinical laboratory assessments.
- Participants must have a BMI of 18 to 30 kg/m^2, inclusive, and total body weight ≥ 50 kg.
Exclusion Criteria:
- Participants must not have presence or history of any clinically relevant abnormality, condition, or disease-CNS, cardiovascular, renal, hepatic, hematologic, GI, endocrine, pulmonary, psychiatric, neurologic (eg, seizure disorder), or immunologic.
- Participants must not have history of rhabdomyolysis.
- Participants must not have current or recent (within 3 months of study intervention administration) clinically significant GI disease.
- Other protocol defined inclusion/exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BMS-986521: Cohort 1
|
Specified dose on specified days
|
|
Experimental: BMS-986521: Cohort 2
|
Specified dose on specified days
|
|
Experimental: BMS-986521: Cohort 3
|
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage occupancy of M4 receptor in the brain
Time Frame: Up to approximately 28 hours after last dose
|
Based on PET scans
|
Up to approximately 28 hours after last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-emergent AEs (TEAEs)
Time Frame: Up to Day 38
|
Up to Day 38
|
|
|
Number of participants with treatment-emergent serious AEs (SAEs)
Time Frame: Up to Day 38
|
Up to Day 38
|
|
|
Number of participants with treatment-emergent suicidal ideation and behavior
Time Frame: Up to Day 11
|
Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
|
Up to Day 11
|
|
Maximum Concentration (Cmax) of BMS-986521 in Plasma
Time Frame: Up to Day 11
|
Up to Day 11
|
|
|
Area Under the Concentration-Time Curve from Time Zero to 24 Hours (AUC(0-24)) of BMS-986521 in Plasma
Time Frame: Up to Day 11
|
Up to Day 11
|
|
|
Time to Cmax (Tmax) of BMS-986521 in Plasma
Time Frame: Up to Day 11
|
Up to Day 11
|
|
|
Effective half-life (T-HALFeff) of BMS-986521 in Plasma
Time Frame: Up to Day 11
|
Up to Day 11
|
|
|
Apparent Clearance of BMS-986521 from Plasma after Dosing (CLT/F)
Time Frame: Up to Day 11
|
Up to Day 11
|
|
|
Apparent Volume of Distribution in Plasma after Dosing (Vz/F) of BMS-986521
Time Frame: Up to Day 11
|
Up to Day 11
|
|
|
Maximal effect (Emax)
Time Frame: Up to approximately 28 hours after last dose
|
Plasma concentrations of BMS-986521 versus M4 receptor occupancy
|
Up to approximately 28 hours after last dose
|
|
Half maximal effective concentration (EC50)
Time Frame: Up to approximately 28 hours after last dose
|
Plasma concentrations of BMS-986521 versus M4 receptor occupancy
|
Up to approximately 28 hours after last dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CN014-0003
- EU CTR (Other Identifier: 2025-521908-22)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.